Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Isabel Cuartas Clear advanced filters

  • LIF is a pleiotropic cytokine that promotes an immunosuppressive microenvironment and has critical functions in embryonic development. Here, the authors show that LIF regulates CD8+ T cell tumor infiltration in cancer by repressing CXCL19 and promoting the presence of protumoral macrophages and thatLIF inhibition, via neutralizing antibodies, promotes T cell infiltration and synergizes with immune checkpoint inhbitors resulting in tumor regression and immunological memory.

    • Mónica Pascual-García
    • Ester Bonfill-Teixidor
    • Joan Seoane
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-11

  • VVD-133214, a clinical-stage, covalent allosteric inhibitor of the helicase WRN, was well tolerated in mice and led to robust tumour regression in multiple microsatellite-instability-high colorectal cancer cell lines and patient-derived xenograft models.

    • Kristen A. Baltgalvis
    • Kelsey N. Lamb
    • Todd M. Kinsella
    Research
    Nature
    Volume: 629, P: 435-442

  • Myc has been implicated in the development of multiple types of cancer. Here, the authors explore the therapeutic potential and mechanism of action of Myc inhibition in mouse and human models of glioblastoma, an aggressive type of tumour that is often resistant to conventional therapy.

    • Daniela Annibali
    • Jonathan R. Whitfield
    • Laura Soucek
    ResearchOpen Access
    Nature Communications
    Volume: 5, P: 1-11

  • TGF-β signaling is commonly aberrantly activated in gliomas and other tumors and can exert a pro-oncogenic function. The authors identify a new mechanism for upregulation of TGF-β signaling in cancer. The deubiquitinase USP15 is shown to be able to bind the TGF-β receptor complex, counteract its degradation and potentiate its stimulation of downstream mediators. USP15 is amplified in human glioblastoma and could represent a therapeutic target, as its downregulation impairs the growth of glioblastoma cells in vivo.

    • Pieter J A Eichhorn
    • Laura Rodón
    • Joan Seoane
    Research
    Nature Medicine
    Volume: 18, P: 429-435